This study will recruit patients from approximately 40 clinical sites from a broad geographic distribution in Japan. Subject enrollment will be monitored to obtain 4 subgroups of 500 patients each segmented by drug class with enrollment closing when a cap of 500 patients is reached. Investigators may recruit patients into any drug subgroup in any order until the study cap is reached. Additional subgroups may be added as new drugs are approved. Additional patients may be added to maintain subgroup numbers.